Document Detail

CA19-9 epitope a possible marker for MUC-1/Y protein.
MedLine Citation:
PMID:  11295060     Owner:  NLM     Status:  MEDLINE    
It has been reported that MUC-1 molecules devoid of the tandem repeat region (MUC-1/Y) are detected preferentially in carcinoma cells and are associated with their progression. However, its clinical significance is still unknown. We constructed a mouse colon adenocarcinoma cell line (MC-38) transduced with either MUC-1/Y cDNA defecting the tandem repeat region (Y-MC-38) or MUC-1/R cDNA containing ten tandem repeats (R-MC-38). RT-PCR of mRNAs derived from Y-MC-38 cells using the specific primers to MUC-1/Y mRNAs, proved the existence of 600 bp RT-PCR products generated only from MUC-1/Y mRNAs. DF3 and CA19-9 epitopes out of the MUC-1-related tumor-associated antigens, have been reported to be involved in the prognosis of cancer patients. We examined the expression of DF3 and CA19-9 epitopes on Y-MC-38 and R-MC-38 cells. Fluorescence-activated cell sorting (FACS) analysis of R-MC-38 and Y-MC-38 cells using two monoclonal antibodies against DF3 (mAb DF3) and CA19-9 (mAb CA19-9) epitopes revealed that R-MC-38 cells expressed DF3 but not CA19-9 [DF3(+)CA19-9(-)], while Y-MC-38 cells expressed CA19-9 but not DF3 [DF3(-)CA19-9(+)]. On Western blot, a 40 kDa protein product was recognized by mAb CA19-9 but not by mAb DF3 on cell lysates of Y-MC-38 cells, whereas a 70 kDa protein product was recognized by mAb DF3 but not by mAb CA19-9 on the cell lysates of R-MC-38. Further, we analyzed the expression of MUC-1/Y mRNAs by RT-PCR on various human cancer cell lines: the gastric cancer cell line AZ521, the pancreatic cancer cell lines PANC-1 and Capan-1, the gall bladder cell line GBK-1, the breast cancer cell line MCF-7, and the colon cancer cell lines HT-29 and Colo205. HT-29 and Capan-1 cells producing the 600 bp RT-PCR product, were positive for mAb CA19-9. These results demonstrate that CA19-9 epitope is produced only on MUC-1/Y core protein, suggesting that CA19-9 epitope may be a specific marker for MUC-1/Y protein.
J Akagi; E Takai; Y Tamori; K Nakagawa; M Ogawa
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  International journal of oncology     Volume:  18     ISSN:  1019-6439     ISO Abbreviation:  Int. J. Oncol.     Publication Date:  2001 May 
Date Detail:
Created Date:  2001-04-11     Completed Date:  2001-06-07     Revised Date:  2008-11-21    
Medline Journal Info:
Nlm Unique ID:  9306042     Medline TA:  Int J Oncol     Country:  Greece    
Other Details:
Languages:  eng     Pagination:  1085-91     Citation Subset:  IM    
National Kumamoto-Minami Hospital, Kumamoto 869-0593, Japan.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Adenocarcinoma / metabolism*,  pathology
Amino Acid Sequence
Blotting, Western
CA-19-9 Antigen / metabolism*
Colonic Neoplasms / metabolism*,  pathology
DNA Primers / chemistry
Fluorescent Antibody Technique, Indirect
Genetic Vectors
Molecular Sequence Data
Mucin-1 / genetics,  metabolism*
Reverse Transcriptase Polymerase Chain Reaction
Tumor Cells, Cultured
Tumor Markers, Biological / biosynthesis
Reg. No./Substance:
0/CA-19-9 Antigen; 0/DNA Primers; 0/Mucin-1; 0/Tumor Markers, Biological

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Protein kinase C activation by PMA rapidly induces apoptosis through caspase-3/CPP32 and serine prot...
Next Document:  Basic fibroblast growth factor in mesothelioma pleural effusions: correlation with patient survival ...